Filtered By:
Source: European Heart Journal
Condition: Cholesterol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Stroke and coronary heart disease: predictive power of standard risk factors into old age--long-term cumulative risk study among men in Gothenburg, Sweden
Conclusion The prediction of traditional risk factors (systolic blood pressure, total serum cholesterol, and smoking status) on short-term risk (0–10 years) and long-term risk (0–35 years) of CHD of stroke differs substantially. This indicates that the cumulative risk in middle-aged men based on these traditional risk factors can effectively be used to predict CHD but not stroke to the same extent.
Source: European Heart Journal - April 7, 2013 Category: Cardiology Authors: Giang, K. W., Bjorck, L., Novak, M., Lappas, G., Wilhelmsen, L., Toren, K., Rosengren, A. Tags: Prevention and epidemiology Source Type: research

Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study
ConclusionHigh variability in lipid levels is associated with adverse health-related outcomes. These findings suggest that lipid variability is an important risk factor in the general population.
Source: European Heart Journal - October 21, 2017 Category: Cardiology Source Type: research

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract
ConclusionLong-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.
Source: European Heart Journal - April 27, 2018 Category: Cardiology Source Type: research

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke
ConclusionPCSK9 genetic variants that confer life-long lower PCSK9 and LDL-C levels appear to have significantly weaker, if any, associations with risk of IS than with risk of CHD. By contrast, similar proportional reductions in risks of IS and CHD have been observed in randomized trials of therapeutic PCSK9-inhibition. These findings have implications for our understanding of when Mendelian randomization can be relied upon to predict the effects of therapeutic interventions.
Source: European Heart Journal - July 17, 2017 Category: Cardiology Source Type: research

Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study
Conclusion The heterogeneity in the risk factor–CVD associations supports the concept of pathophysiological differences between atherosclerotic CVD manifestations and could have implications for CVD prevention.
Source: European Heart Journal - March 14, 2016 Category: Cardiology Authors: Stoekenbroek, R. M., Boekholdt, S. M., Luben, R., Hovingh, G. K., Zwinderman, A. H., Wareham, N. J., Khaw, K.-T., Peters, R. J. G. Tags: Prevention and epidemiology Source Type: research

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study
Conclusion Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost-effective.
Source: European Heart Journal - February 1, 2014 Category: Cardiology Authors: McConnachie, A., Walker, A., Robertson, M., Marchbank, L., Peacock, J., Packard, C. J., Cobbe, S. M., Ford, I. Tags: Prevention and epidemiology Source Type: research

Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry
Conclusion Among patients with PAD in the REACH registry, statin use was associated with an ~18% lower rate of adverse limb outcomes, including worsening symptoms, peripheral revascularization, and ischaemic amputations. These findings suggest that statin therapy not only reduces the risk of adverse cardiovascular events, but also favourably affects limb prognosis in patients with PAD.
Source: European Heart Journal - November 1, 2014 Category: Cardiology Authors: Kumbhani, D. J., Steg, P. G., Cannon, C. P., Eagle, K. A., Smith, S. C., Goto, S., Ohman, E. M., Elbez, Y., Sritara, P., Baumgartner, I., Banerjee, S., Creager, M. A., Bhatt, D. L., on Behalf of the REACH Registry Investigators Tags: Vascular medicine Source Type: research

Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Conclusion In this 1-year follow-up analysis of the EORP-AF pilot general registry, we provide data on the first contemporary registry focused on management practices among European cardiologists, conducted since the publication of the new ESC guidelines. Overall OAC use remains high, although persistence with therapy may be problematic. Nonetheless, continued OAC use was more common than in prior reports. Despite the high prescription of OAC, 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations.
Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Fast Track ESC Clinical Trial and Registry Update Source Type: research

Association between pre-operative statin use and major cardiovascular complications among patients undergoing non-cardiac surgery: the VISION study
Conclusion Among patients undergoing non-cardiac surgery, pre-operative statin therapy was independently associated with a lower risk of cardiovascular outcomes at 30 days. These results require confirmation in a large randomized trial. Clinical trial registration Clinical Trials.gov NCT00512109
Source: European Heart Journal - January 7, 2016 Category: Cardiology Authors: Berwanger, O., Le Manach, Y., Suzumura, E. A., Biccard, B., Srinathan, S. K., Szczeklik, W., Santo, J. A. E., Santucci, E., Cavalcanti, A. B., Archbold, R. A., Devereaux, P. J., for the VISION Investigators Tags: ESC Clinical Registry Source Type: research

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
ConclusionRoutine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events.Trial registrationClinicalTrials.gov, number NCT00741585. 
Source: European Heart Journal - October 22, 2019 Category: Cardiology Source Type: research

Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Conclusions  Larger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.
Source: European Heart Journal - December 24, 2020 Category: Cardiology Source Type: research

N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS
Conclusion N-terminal pro-B-type natriuretic peptide predicts CVD events in men without clinical evidence of CHD, angina, or history of stroke, and appears related more strongly to the risk for fatal events. N-terminal pro-B-type natriuretic peptide also provides moderate risk discrimination, in excess of that provided by the measurement of C-reactive protein. Clinical trial registration WOSCOPS was carried out and completed prior to the requirement for clinical trial registration.
Source: European Heart Journal - February 7, 2013 Category: Cardiology Authors: Welsh, P., Doolin, O., Willeit, P., Packard, C., Macfarlane, P., Cobbe, S., Gudnason, V., Di Angelantonio, E., Ford, I., Sattar, N. Tags: Prevention/epidemiology Source Type: research

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis
Conclusion Statin therapy reduces the risk of major cardiovascular events in patients with chronic kidney disease including those receiving dialysis.
Source: European Heart Journal - June 21, 2013 Category: Cardiology Authors: Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M. J., Cass, A., Zhang, H., Wang, H. Tags: Prevention and epidemiology Source Type: research

The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk
Conclusions These findings suggest that CAD/MI-associated risk alleles play an aetiological role in different types of atherosclerotic disease.
Source: European Heart Journal - October 1, 2013 Category: Cardiology Authors: Tragante, V., Doevendans, P. A. F. M., Nathoe, H. M., van der Graaf, Y., Spiering, W., Algra, A., de Borst, G. J., de Bakker, P. I. W., Asselbergs, F. W., on behalf of the SMART study group Tags: Coronary artery disease Source Type: research